PHAT Earnings Prediction
The chart below shows how PHAT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PHAT sees a -0.01% change in stock price 10 days leading up to the earnings, and a -8.30% change 10 days following the report. On the earnings day itself, the stock moves by -0.34%. This data can give you a slight idea of what to expect for the next quarter's release.
PHAT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
16.35M
--
123.27%
Gross Margin
85.59%
--
5.39%
Operating Margin
-432.95%
--
-58.98%
Net Margin
-523.34%
--
-58.09%
EPS
-1.32
-73.68%
-15.38%
No Data Available
PHAT Earnings Analysis
Phathom Pharmaceuticals, Inc. Common Stock Corporation (PHAT.O) Earnings Conference Call
Positive
VOQUEZNA Launch Priorities: Successful commercial launch of VOQUEZNA remains our top priority, with growing interest from physicians and patients, and increased coverage from payers.
Quarterly Revenue Surge: In the third quarter of 2024, we achieved net revenues of $16.4 million, representing over 120% sequential quarter-over-quarter increase.
FDA Approval for VOQUEZNA: We secured FDA approval for VOQUEZNA as a treatment for non-Erosive GERD, greatly expanding commercial access, now covering over 80% of lives.
Gross Profit Increase: We reported gross profit of $14 million, equating to a gross margin of 86%, an increase of about 440 basis points over last quarter.
R&D Spend Decrease: We reported non-GAAP R&D spend of $7.4 million for the third quarter, reflecting a 32% decrease compared to Q3 2023.
Negative
Revenue Decline Q3 2024: Net revenues reported for Q3 2024 were $16.4 million, reflecting a significant decline compared to previous quarters.
R&D Spend Decrease: Non-GAAP R&D spend for Q3 2024 was $7.4 million, representing a 32% decrease compared to Q3 2023.
Net Loss Comparison: Reported a net loss of $67.9 million for Q3 2024, or $1.05 loss per share, compared to a loss of $73.3 million or $1.25 loss per share in Q2 2024.
Operating Expenses Surge: Operating expenses increased to $71.8 million for Q3 2024, an increase of $53.1 million compared to the same period in 2023.
Gross Profit Decline: Gross profit for Q3 2024 was reported at $14 million, equating to a gross margin of 86%, which is a decline from previous margins.
PHAT FAQs
How does PHAT typically perform around its earnings report dates?
Is Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PHAT Earning Call Sentiment
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PHAT.O
-14.24%Positive
The earnings call summary highlights strong financial performance with a significant increase in net revenues and gross profit. The launch of VOQUEZNA has shown promising results, with strong market interest and expanded commercial coverage. Despite a net loss, the company has a healthy cash position and potential peak revenue opportunities. The Q&A section reveals a positive sentiment towards demand and insurance coverage expansion, but some concerns about refill rates and trial ROI. Overall, the optimism from revenue growth and market expansion outweighs the financial and regulatory risks.
